Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05461014 · ClinicalTrials.gov registry record · NA
RxWell in Pediatric IBD for Disease Management and Transition Readiness
A NA study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT05461014: Clinical Trial NA study, sponsored by University of Pittsburgh.
NCT05461014 is a NA study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05461014, a NA study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
Evaluate the feasibility and acceptability of adapted coached RxWell for patients ages 16-25. Adapt and beta test the modified RxWell product to include chronic disease management and transition readiness. Evaluate RxWell usage and its impact to the TRAQ questionnaire over time.
Primary Outcome
Generalized Anxiety Disorder 7 measures anxiety severity (score ranges from 0-21, with 21 being severe anxiety) is completed within the app and at three study timepoints (baseline, 3 months and 6 months). This measure will be studied over time, up to 6 months.
Interventions
- BEHAVIORAL dCBI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-07-30 |
| Est. Completion | 2023-03-08 |
| Phase | NA |
Why NCT05461014 stopped before completion
NCT05461014 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which dCBI is the first listed.
NCT05461014 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05461014 about?
NCT05461014 is a clinical study titled "RxWell in Pediatric IBD for Disease Management and Transition Readiness". Evaluate the feasibility and acceptability of adapted coached RxWell for patients ages 16-25. Adapt and beta test the modified RxWell product to include chronic disease management and transition readiness. Evaluate RxWell usage and its impact to the TRAQ questionnaire over time.
What is the current status of trial NCT05461014?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2022-07-30. Estimated completion is 2023-03-08.
What interventions are being tested in trial NCT05461014?
The interventions under investigation include: dCBI (BEHAVIORAL).
Who is sponsoring clinical trial NCT05461014?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05461014's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI